ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) Stock Overview
NASDAQ:ADAP - US00653A1079 - ADR
ADAP Key Statistics, Chart & Performance
The current stock price of ADAP is 0.0569 USD. In the past month the price decreased by -83.6%. In the past year, price decreased by -95.3%.
ADAP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.89 | 372.04B | ||
| AMGN | AMGEN INC | 13.47 | 158.13B | ||
| GILD | GILEAD SCIENCES INC | 14.83 | 142.41B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.32 | 101.30B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.92 | 62.48B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.56B | ||
| ARGX | ARGENX SE - ADR | 71.2 | 40.39B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.35 | 37.29B | ||
| INSM | INSMED INC | N/A | 27.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.66B | ||
| NTRA | NATERA INC | N/A | 22.73B | ||
| BIIB | BIOGEN INC | 8.7 | 20.42B |
Related stock screener links
About ADAP
Company Profile
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. The company is headquartered in Abingdon, Oxfordshire and currently employs 506 full-time employees. The company went IPO on 2015-05-06. The firm is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The firm is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Company’s most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.
Company Info
ADAPTIMMUNE THERAPEUTICS-ADR
60 Jubilee Avenue, Milton Park
Abingdon OXFORDSHIRE OX14 4RX GB
CEO: Adrian Rawcliffe
Employees: 506
Phone: 441235430000
ADAPTIMMUNE THERAPEUTICS-ADR / ADAP FAQ
What is the stock price of ADAPTIMMUNE THERAPEUTICS-ADR today?
The current stock price of ADAP is 0.0569 USD. The price decreased by -2.74% in the last trading session.
What is the ticker symbol for ADAPTIMMUNE THERAPEUTICS-ADR stock?
The exchange symbol of ADAPTIMMUNE THERAPEUTICS-ADR is ADAP and it is listed on the Nasdaq exchange.
On which exchange is ADAP stock listed?
ADAP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ADAPTIMMUNE THERAPEUTICS-ADR stock?
12 analysts have analysed ADAP and the average price target is 0.36 USD. This implies a price increase of 527.42% is expected in the next year compared to the current price of 0.0569. Check the ADAPTIMMUNE THERAPEUTICS-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ADAPTIMMUNE THERAPEUTICS-ADR worth?
ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) has a market capitalization of 15.08M USD. This makes ADAP a Nano Cap stock.
How many employees does ADAPTIMMUNE THERAPEUTICS-ADR have?
ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) currently has 506 employees.
Is ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) expected to grow?
The Revenue of ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) is expected to decline by -77.84% in the next year. Check the estimates tab for more information on the ADAP EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ADAP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ADAP, evaluating the profitability, health, valuation and growth aspects
- ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) Sales and EPS estimates to see what analysts future expectations are.
- ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) Insider and Institutional Ownership to learn about the owners and their transactions.
- ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) Stock Chart to make your own analysis
- ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) Latest news and press-releases to stay up to date.
Does ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) stock pay dividends?
ADAP does not pay a dividend.
When does ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) report earnings?
ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) will report earnings on 2025-11-11, before the market open.
What is the Price/Earnings (PE) ratio of ADAPTIMMUNE THERAPEUTICS-ADR (ADAP)?
ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.46).
What is the Short Interest ratio of ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) stock?
The outstanding short interest for ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) is 19.01% of its float. Check the ownership tab for more information on the ADAP short interest.
ADAP Technical Analysis
ADAP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADAP. Both the profitability and financial health of ADAP have multiple concerns.
ADAP Financial Highlights
Over the last trailing twelve months ADAP reported a non-GAAP Earnings per Share(EPS) of -0.46. The EPS decreased by -21.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -129.95% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ADAP Forecast & Estimates
12 analysts have analysed ADAP and the average price target is 0.36 USD. This implies a price increase of 527.42% is expected in the next year compared to the current price of 0.0569.
For the next year, analysts expect an EPS growth of -125.47% and a revenue growth -77.84% for ADAP